Epica International’s mobile imaging platform gains FDA approval

Michael Walter | | Radiology Business | Practice Management

Epica International, a San Clemente, California-based medical imaging technology company, has received FDA clearance for its multi-modality mobile imaging platform.

The platform, SeeFactorCT3, can be used to obtain CT scans, fluoroscopy and digital x-rays. It also includes a detachable patient table/chair and drape for interventional procedures. It was designed to be used by physicians, technologists, surgeons and dentists for a variety of procedures.

“I am very pleased to announce this major milestone event in Epica’s history, our progression into the human medical space,” Frank D. D’Amelio, CEO of Epica International, said in a prepared statement.

In the same statement, Epica promoted the ongoing development of its Medical Robot prototypes, which “will allow physicians to visualize target anatomy, plan surgical intervention and then execute the procedure wit the surgeon’s preferred instruments.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

US Radiology Specialists affiliate expands into new market
Navigating the radiology workforce shortage: 6 potential solutions
Radiologist rails against insurer’s refusal to cover key interventional service
Blue Cross Blue Shield affiliate rejects MRI contrast coverage, labeling it ‘investigational’
Radiology experts say state Medicaid rates must increase to improve imaging access
Can large language models break language barriers in radiology reports?

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.